Citi upgraded Blueprint Medicines (BPMC) to Neutral from Sell with a price target of $129, up from $83, following the announcement that Blueprint will be acquired by Sanofi (SNY) in a cash transaction of $129 per share plus contingent value rights considerations for pipeline asset BLU-80. At this time, Citi does not expect regulatory hurdles or competitive bids to impact the transaction.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint Medicines downgraded to Neutral from Buy at Guggenheim
- Reddit initiated, Pinterest upgraded: Wall Street’s top analyst calls
- Blueprint Medicines downgraded to Equal Weight from Overweight at Stephens
- Blueprint downgraded to Market Perform from Outperform at Citizens JMP
- Blueprint Medicines downgraded to Hold from Buy at TD Cowen